Zymeworks Inc.
ZYME Real Time Price USDRecent trades of ZYME by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in ZYME holdings by institutional investors
Quarterly net insider trading by ZYME's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
ZYME Estimated quarterly lobbying spending
ZYME Revenue by Segment or Geography
New ZYME patent grants
-
Patent Title: Bispecific antigen-binding constructs targeting her2 May. 10, 2022
-
Patent Title: Modified antigen binding polypeptide constructs and uses thereof Apr. 19, 2022
-
Patent Title: Engineered immunoglobulin heavy chain-light chain pairs and uses thereof Mar. 29, 2022
-
Patent Title: Multivalent heteromultimer scaffold design and constructs Feb. 15, 2022
-
Patent Title: Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof Nov. 02, 2021
-
Patent Title: Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics Oct. 19, 2021
-
Patent Title: Drug-conjugated bi-specific antigen-binding constructs Oct. 19, 2021
-
Patent Title: Heteromultimers with reduced or silenced effector function Aug. 24, 2021
-
Patent Title: Engineered immunoglobulin heavy chain-light chain pairs and uses thereof Aug. 03, 2021
-
Patent Title: Systems and methods for identifying thermodynamically relevant polymer conformations Jun. 08, 2021
-
Patent Title: Antigen-binding constructs targeting her2 Jun. 08, 2021
-
Patent Title: Anti-her2 biparatopic antibody-drug conjugates and methods of use May. 11, 2021
-
Patent Title: Bispecific antigen-binding constructs targeting her2 Mar. 16, 2021
-
Patent Title: Stable heterodimeric antibody design with mutations in the fc domain Dec. 29, 2020
-
Patent Title: System for molecular packing calculations Nov. 10, 2020
-
Patent Title: Multivalent heteromultimer scaffold design and constructs Jul. 14, 2020
-
Patent Title: Compositions and methods for the treatment of platinum-drug resistant cancer Dec. 31, 2019
-
Patent Title: Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells Dec. 17, 2019
-
Patent Title: Systems and methods for sampling and analysis of polymer conformational dynamics Nov. 19, 2019
-
Patent Title: Stable heterodimeric antibody design with mutations in the fc domain Oct. 29, 2019
-
Patent Title: Cytotoxic and anti-mitotic compounds, and methods of using the same Oct. 22, 2019
-
Patent Title: Cytotoxic and anti-mitotic compounds, and methods of using the same Sep. 17, 2019
-
Patent Title: Multivalent heteromultimer scaffold design and constructs Jul. 23, 2019
-
Patent Title: Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof Apr. 30, 2019
-
Patent Title: Systems and methods for in silico evaluation of polymers Apr. 09, 2019
-
Patent Title: Systems and methods for making two dimensional graphs of complex molecules Apr. 09, 2019
-
Patent Title: Bispecific her2 and her3 antigen binding constructs Mar. 26, 2019
-
Patent Title: Cytotoxic and anti-mitotic compounds, and methods of using the same Feb. 12, 2019
-
Patent Title: Systems and methods for making two dimensional graphs of complex molecules Jan. 01, 2019
-
Patent Title: Multivalent heteromultimer scaffold design and constructs Dec. 18, 2018
-
Patent Title: Engineered immunoglobulin heavy chain-light chain pairs and uses thereof Sep. 18, 2018
-
Patent Title: Simplifying residue relationships in protein design Jun. 19, 2018
-
Patent Title: Bispecific antigen-binding constructs targeting her2 Jun. 19, 2018
-
Patent Title: Crystal structures of heterodimeric fc domains Jun. 05, 2018
-
Patent Title: Engineered immunoglobulin heavy chain-light chain pairs and uses thereof Mar. 13, 2018
-
Patent Title: Cytotoxic and anti-mitotic compounds, and methods of using the same Jan. 30, 2018
-
Patent Title: Methods of quantitating heavy and light chain polypeptide pairs Sep. 26, 2017
-
Patent Title: Crystal structures of heterodimeric fc domains Aug. 15, 2017
-
Patent Title: Systems and methods for identifying thermodynamic effects of atomic changes to polymers Jul. 04, 2017
-
Patent Title: Stable heterodimeric antibody design with mutations in the fc domain Feb. 21, 2017
-
Patent Title: Stable heterodimeric antibody design with mutations in the fc domain Feb. 07, 2017
-
Patent Title: Cytotoxic and anti-mitotic compounds, and methods of using the same Dec. 20, 2016
-
Patent Title: Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells Nov. 22, 2016
-
Patent Title: Multivalent heteromultimer scaffold design and constructs Nov. 22, 2016
-
Patent Title: Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics Aug. 02, 2016
-
Patent Title: Multivalent heteromultimer scaffold design and constructs Jul. 12, 2016
-
Patent Title: Antibodies with enhanced or suppressed effector function Mar. 29, 2016
-
Patent Title: Density based clustering for multidimensional data Oct. 20, 2015
-
Patent Title: System and method for modeling interactions Aug. 03, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded to ZYME from public contracts
Recent insights relating to ZYME
Recent picks made for ZYME stock on CNBC
ETFs with the largest estimated holdings in ZYME
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ZYME stock a Buy, Sell, or Hold?
- What is the price target for $ZYME stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ZYME stock?
- Who owns the most shares of $ZYME stock?
- What funds own $ZYME stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ZYME Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
- Address Middletown, DE
- Market Cap 1.8 billion
- Employees 273
- Industrial Classification Pharmaceutical Preparations